Henry Schein Inc HSIC
We take great care to ensure that the data presented and summarized in this overview for HENRY SCHEIN INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding HSIC
View all-
Vanguard Group Inc Valley Forge, PA15.4MShares$1.15 Billion0.02% of portfolio
-
Generation Investment Management LLP London, X010.1MShares$756 Million3.56% of portfolio
-
Black Rock Inc. New York, NY9.8MShares$731 Million0.02% of portfolio
-
State Street Corp Boston, MA6.39MShares$477 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA6.26MShares$467 Million0.1% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI6.07MShares$453 Million0.71% of portfolio
-
American Century Companies Inc Kansas City, MO5.32MShares$397 Million0.26% of portfolio
-
Jpmorgan Chase & CO New York, NY5.16MShares$385 Million0.04% of portfolio
-
Pendal Group LTD4.18MShares$312 Million2.74% of portfolio
-
Geode Capital Management, LLC Boston, MA3.16MShares$236 Million0.02% of portfolio
Latest Institutional Activity in HSIC
Top Purchases
Top Sells
About HSIC
Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Insider Transactions at HSIC
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
Stanley M Bergman Chairman, CEO |
SELL
Bona fide gift
|
Indirect |
1,119
-0.23%
|
-
|
Mar 20
2024
|
Bradford C Connett CEO, NA Distribution Group |
SELL
Open market or private sale
|
Direct |
6,430
-8.08%
|
$475,820
$74.28 P/Share
|
Mar 20
2024
|
Stanley M Bergman Chairman, CEO |
SELL
Bona fide gift
|
Indirect |
475
-0.1%
|
-
|
Mar 18
2024
|
James P Breslawski Vice Chairman, President |
SELL
Open market or private sale
|
Direct |
2,907
-1.37%
|
$215,118
$74.37 P/Share
|
Mar 09
2024
|
Ronald N. South SVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,064
+22.29%
|
-
|
Mar 09
2024
|
Michael S Ettinger EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,752
+21.09%
|
-
|
Mar 09
2024
|
Mark E Mlotek EVP, Chief Strategic Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,752
+22.75%
|
-
|
Mar 09
2024
|
Bradford C Connett CEO, NA Distribution Group |
BUY
Grant, award, or other acquisition
|
Direct |
23,408
+22.74%
|
-
|
Mar 06
2024
|
Stanley M Bergman Chairman, CEO |
SELL
Bona fide gift
|
Direct |
460
-0.17%
|
-
|
Mar 05
2024
|
Philip A Laskawy |
SELL
Open market or private sale
|
Direct |
4,278
-14.83%
|
$325,128
$76.29 P/Share
|
Mar 04
2024
|
Stanley M Bergman Chairman, CEO |
BUY
Grant, award, or other acquisition
|
Direct |
101,117
+27.27%
|
-
|
Mar 04
2024
|
Reed Vaughn Tuckson |
BUY
Grant, award, or other acquisition
|
Direct |
2,604
+24.2%
|
-
|
Mar 04
2024
|
Walter Siegel Sr. VP & Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,441
+17.78%
|
-
|
Mar 04
2024
|
Scott Philip Serota |
BUY
Grant, award, or other acquisition
|
Direct |
2,604
+30.47%
|
-
|
Mar 04
2024
|
Bradley T Sheares |
BUY
Grant, award, or other acquisition
|
Direct |
2,604
+5.74%
|
-
|
Mar 04
2024
|
Carol Raphael |
BUY
Grant, award, or other acquisition
|
Direct |
2,604
+7.55%
|
-
|
Mar 04
2024
|
Steven Paladino |
BUY
Grant, award, or other acquisition
|
Direct |
2,604
+1.85%
|
-
|
Mar 04
2024
|
Lorelei Mc Glynn SVP, Chief Human Res. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,566
+11.92%
|
-
|
Mar 04
2024
|
Philip A Laskawy |
BUY
Grant, award, or other acquisition
|
Direct |
2,604
+8.28%
|
-
|
Mar 04
2024
|
Anne H. Margulies |
BUY
Grant, award, or other acquisition
|
Direct |
2,604
+11.38%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 268K shares |
---|
Payment of exercise price or tax liability | 20K shares |
---|---|
Open market or private sale | 167K shares |
Bona fide gift | 6.86K shares |
Other acquisition or disposition | 3.5K shares |